DNA methylation and expression of MAPRE3 affect overall survival of early-stage non-small cell lung cancer patients


Por: Chen, C, Cheng, JC, Hou, RL, Zheng, XY, Su, L, Bjaanæs, MM, Karlsson, A, Planck, M, Staaf, J, Helland, Å, Esteller, M, Christiani, DC, Chen, F, Cao, XF and Zhang, RY

Publicada: 25 abr 2026 Ahead of Print: 1 abr 2026
Resumen:
The MAPRE3 gene is aberrantly expressed in several cancers. We profiled DNA methylation in tumor tissues from early-stage non-small cell lung cancer (NSCLC) patients and assessed associations with overall survival (OS). Significant CpG probes were validated in The Cancer Genome Atlas (TCGA). The methylation level of cg12821679MAPRE3 showed significant associations with OS in lung squamous cell carcinoma (LUSC) (HR = 0.32, P = 6.55 & times; 10-7), but it was not observed in lung adenocarcinoma (LUAD). In LUSC, MAPRE3 expression was significantly correlated with cg12821679MAPRE3 (r = 0.17, P = 2.96 & times; 10-3) and potential trans-regulated genes were enriched in the Nicotine addiction pathway. Additionally, MAPRE3 expression showed significant associations with OS in both LUAD and LUSC (LUAD: HRlow vs high = 2.28, P = 2.40 & times; 10-3; LUSC: HRlow vs high = 1.61, P = 0.0244). The association between smoking cessation and overall survival was significantly modified by MAPRE3 expression (HRinteraction = 0.69, P = 0.0282). Smoking cessation improved OS only in patients with high MAPRE3 expression (HR = 0.56, P = 2.82 & times; 10-3). We conclude MAPRE3 may predict NSCLC prognosis and influence the prognostic benefit of smoking cessation.

Filiaciones:
Chen, C:
 Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China

Cheng, JC:
 Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China

Hou, RL:
 Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China

Zheng, XY:
 Nanjing Med Univ, Peoples Hosp Changzhou 2, Affiliated Hosp 3, Informat Ctr, Nanjing, Jiangsu, Peoples R China

Su, L:
 Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA

Bjaanæs, MM:
 Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway

Karlsson, A:
 Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden

 Lund Univ, CREATE Hlth Strateg Ctr Translat Canc Res, Lund, Sweden

Planck, M:
 Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden

 Lund Univ, CREATE Hlth Strateg Ctr Translat Canc Res, Lund, Sweden

Staaf, J:
 Lund Univ, Dept Clin Sci Lund, Div Oncol, Lund, Sweden

 Lund Univ, CREATE Hlth Strateg Ctr Translat Canc Res, Lund, Sweden

Helland, Å:
 Oslo Univ Hosp, Inst Canc Res, Dept Canc Genet, Oslo, Norway

 Univ Oslo, Inst Clin Med, Oslo, Norway

:
 Josep Carreras Leukaemia Res Inst IJC, Canc Epigenet Grp, Barcelona, Spain

 Ctr Invest Biomed Red Canc CIBERONC, Madrid, Spain

 Inst Catalana Recerca & Estudis Avancats, Barcelona, Spain

 Univ Barcelona, Sch Med & Hlth Sci, Physiol Sci Dept, Barcelona, Spain

Christiani, DC:
 Harvard TH Chan Sch Publ Hlth, Dept Environm Hlth, Boston, MA USA

 Massachusetts Gen Hosp, Dept Med, Pulm & Crit Care Div, Boston, MA USA

 Harvard Med Sch, Boston, MA USA

Chen, F:
 Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China

 Nanjing Med Univ, China Int Cooperat Ctr Environm & Human Hlth, Nanjing, Jiangsu, Peoples R China

Cao, XF:
 Nanjing Med Univ, Affiliated Hosp 1, Sch Clin Med 1, Dept Anesthesiol & Perioperat Med, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China

Zhang, RY:
 Nanjing Med Univ, Ctr Global Hlth, Sch Publ Hlth, Dept Biostat, 01 Longmian Ave, Nanjing 211166, Jiangsu, Peoples R China

 Nanjing Med Univ, Peoples Hosp Changzhou 2, Affiliated Hosp 3, Informat Ctr, Nanjing, Jiangsu, Peoples R China

 Nanjing Med Univ, Changzhou Med Ctr, Changzhou, Jiangsu, Peoples R China

 Nanjing Med Univ, Lab Digital Intelligence & Hlth Governance, Nanjing, Jiangsu, Peoples R China
ISSN: 15747891





Molecular Oncology
Editorial
John Wiley and Sons Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Países Bajos
Tipo de documento: Article
Volumen: 20 Número: 8
Páginas: 2008-2022
WOS Id: 001748022800001
ID de PubMed: 42033322
imagen gold

MÉTRICAS